Loading
A phase 2 trial of Sirolimus protein-bound particles in endometrial cancer, run by Aadi Bioscience, Inc., now recruiting.
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer is a phase 2 interventional study registered as NCT05997017 by Aadi Bioscience, Inc., with 29 participants planned, started 2023-12-28 and due to reach its primary completion in 2026-12. Interventions recorded: nab-sirolimus. Conditions listed: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor. No results are recorded here; the registry entry is the source.
Shares Aadi Bioscience, Sirolimus protein-bound particles, Small-molecule kinase inhibitors.
Shares Aadi Bioscience, Sirolimus protein-bound particles, Small-molecule kinase inhibitors.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Small-molecule kinase inhibitors.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Small-molecule kinase inhibitors.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Small-molecule kinase inhibitors.